Novo Holdings Venture Investments is one of the largest and most active life science venture investors globally. Primarily investing in companies that develop innovative drugs and novel
technologies, we provide capital, knowledge and a network to companies in the biotechnology and medical technology sectors, spanning early-stage, translatable science through commercial stage products.
The Venture Investments team employs multiple strategies within the life sciences industry including investing in both private equity and publicly traded equities. On the private side, Novo Holdings typically leads or co-leads its investments and takes an active ownership role with board participation. On the public side, Novo Holdings participates in company financings and trades in the open market. With teams based in Copenhagen, London, Singapore, Boston and San Francisco, Novo Holdings is positioned in the world’s leading life science hubs and can engage closely with companies and partners globally. Novo Holdings ’ evergreen structure enables the Venture Investments team to take a long-term view to advance science and medicine for the benefit of society.
17
bn
Portfolio value at year-end 2025
53
Portfolio companies
5
bn
Capital deployed during the year 2025
Search
Meet our team

Reports
01/12/2026
Novo Holdings publishes its 2025 Venture Investments Annual Review and Business Update

News
10/17/2025
Novo Holdings announces acquisition of portfolio company Nalu Medical by Boston Scientific

News
10/9/2025
Novo Holdings co-leads $165 million Series A financing of Expedition Therapeutics to advance next-generation COPD therapy

News
09/30/2025
Novo Holdings co-leads $205 million Series A financing of Crystalys Therapeutics to transform treatment of gout